ERBB2 and breast cancer: Differences in uptake parameters across pathological types, molecular subtypes, and immunohistochemical (ER/PR/HER2/Ki-67) statuses were analyzed using Mann-Whitney U or Kruskal-Wallis H tests.<h4>Results</h4>Of 58 patients, 49 had breast cancer and 9 had benign lesions.